echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > JCEM: Body mass index and contraceptives affect age, sex and puberty-adjusted reference ranges for IGF-I and IGFBP-3

    JCEM: Body mass index and contraceptives affect age, sex and puberty-adjusted reference ranges for IGF-I and IGFBP-3

    • Last Update: 2022-04-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Background : Various clinical factors affecting serum insulin-like growth factor I (IGF-I) and its binding protein 3 (IGFBP-3) levels have not been fully described
    .

    Background : Background Various clinical factors affecting serum insulin-like growth factor I (IGF-I) and its binding protein 3 (IGFBP-3) levels have not been fully described
    .


    Objectives : We asked whether BMI, contraceptives (CDs) and hormone replacement therapy (HRT) have a potential impact on the interpretation of the new age-, sex- and puberty-adjusted reference ranges for serum levels of IGF-I and IGFBP-3
    .

    Objectives : We asked whether BMI, contraceptives (CDs) and hormone replacement therapy (HRT) have a potential impact on the interpretation of the new age-, sex- and puberty-adjusted reference ranges for serum levels of IGF-I and IGFBP-3
    .


    Purpose

    DESIGN AND SETTING : Subject primary participants were drawn from two population-based cohort studies: the 'LIFE Child' study and the 'LIFE Adult' study in children and adolescents
    .


    Participants: 3 months to 81 years


    DESIGN AND SETTING : Subject primary participants were drawn from two population-based cohort studies: the 'LIFE Child' study and the 'LIFE Adult' study in children and adolescents


    Main outcome measures : Association between IGF-I or IGFBP-3, measured with a novel electrochemiluminescence immunoassay, predictors BMI and CDs estimated using hierarchical linear models


    Results : IGF-I had good agreement [concordance correlation coefficient = 0.


    Table 1 Age distribution of non-obese girls (BMI ± 1.


    Table 2 Oral and parenteral combination of estrogen-progestin-based CDs (EpCDs) or progestin-based CDs (PCDS) and estrogen- or estrogen-based hormone replacement therapy (eHRT/eHRT) ) on insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 in adult females (≥19 years of age)
    .


    Beta estimates and corresponding 95% confidence intervals are given


    Table 2 Oral and parenteral combination of estrogen-progestin-based CDs (EpCDs) or progestin-based CDs (PCDS) and estrogen- or estrogen-based hormone replacement therapy (eHRT/eHRT) ) on insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 in adult females (≥19 years of age)


    Table 3 Mean and standard deviation (SD) values ​​for IGF-I and IGFBP-3 and corresponding SDS values ​​for ECLIA and CLIA analyses
    .


    The median, range, mean and SD values ​​of the difference between ECLIA and CLIA are also given


    Table 3 Mean and standard deviation (SD) values ​​for IGF-I and IGFBP-3 and corresponding SDS values ​​for ECLIA and CLIA analyses


    Conclusions: BMI and CD must be considered when assessing and interpreting the clinical relevance of IGF-I and IGFBP-3 measurements
    .

    Conclusions: BMI and CD must be considered when assessing and interpreting the clinical relevance of IGF-I and IGFBP-3 measurements
    .


     

    Original source:

    Original source:

    Hörenz C, Vogel M, Wirkner K, et al.


    Hörenz C, Vogel M, Wirkner K, et al.
    BMI and contraceptives affect new age-, sex-, and puberty-adjusted IGF-I and IGFBP-3 reference ranges across life span.
    J Clin Endocrinol Metab 2022 Mar 16 Comment on this
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.